Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistanceMelissa Dolan, John M.L. Ebos|PLoS ONE|2019Cited by 29
Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatmentSébastien Benzekry, John M.L. Ebos|PLoS Computational Biology|2024Cited by 19
Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cellsYuhao Shi, John M.L. Ebos|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 1